Table 8.
Selected trials of targeted agents for SCC of the esophagus
| Author | Regimen | Pathology | N (SCC) | Line | Response rate (%) |
|---|---|---|---|---|---|
| Janmaat71 | Gefitinib | SCC/adeno | 36 (9) | 2nd | 3 |
| Ku72 | Cetuximab + cisplatin + irinotecan | SCC/adeno | 8 (1) | 2nd* | 11 |
| Lordick70 | Cetuximab + cisplatin + 5-FU | SCC | 32 | 1st | 19 |
| Safran73 | Cetuximab + paclitaxel + carboplatin + RT 50.4 Gy | SCC/adeno | 60 (12) | 1st | cCR 70 |
*
Cisplatin + irinotecan failure
Abbreviations: SCC = squamous-cell carcinoma; adeno = adenocarcinoma; RT = radiotherapy; cCR = clinical complete response